Tutorial disable Twitter Fleets iOS Android: Twitter has joined the fashion for stories through Fleets. Through this functionality the app aims to encourage the interaction of those users who have a Twitter account but do not give it too much use.
They are temporary posts that only last 24 hours. Facebook, Instagram, Linkedin or WhatsApp Stories are very similar to how they work.
on both Android and iOS. At the top of the screen you can view the posts of the accounts you follow, although you will not be able to retweet or like them, just respond by direct message.
Another aspect to keep in mind is that if you click on a user's Fleet, that person can know that you have seen it, just as you can check who is watching your stories.
That Fleets are presented by bubbles at the top of the screen has been annoying for some users, since they occupy a space that was previously free. Because of this, many are wondering how to disable them.
Fleets cannot be deactivated, it is an option that has not been implemented or at least does not yet exist. Of course, there are some alternatives to consider to soften its effect.
Tutorial disable Twitter Fleets iOS Android
The first one is quite effective: mute the Fleets of the accounts you follow, so you will stop seeing the stories of that particular account.
To do so you just have to hold down on one of the bubbles and check the Mute option. Then 2 options open: mute Fleets and mute fleets and tweets. Choose the one that suits you best.
The problem with this possibility is that you have to mute user by user, and if you follow many accounts there will always be one left to mute. Also, there is no way to disable the bubble itself.
Another way to avoid this new Twitter tool is to use the web version. It is very similar to the app , you can use the same basic functions. This does not mean that you have to give up Twitter on your mobile, since it is enough to enter through the browser you use on your smartphone.
So far Fleets have not been included in this version, so it's a good way to avoid them. Of course, it can not be ruled out that they appear in the future.
Tutorial disable Twitter Fleets iOS Android
Internally Beaded Windows | All Spruce (no cheap pine) | 10 Years Guarantee on Treated Timber: GARDEN SHEDS
Scientists evaluating the coronavirus vaccine from the University of Oxford and AstraZeneca are baffled by a crucial figure
The long-awaited initial results of tests of the Covid-19 vaccine from the University of Oxford and AstraZeneca have already arrived, and experts are puzzled by a big question mark.
The headline is that the vaccine works. Oxford and AstraZeneca assure that the vaccine is 70% effective in protecting against COVID-19.
However, that 70% figure is a measure of two efficacy numbers from different vaccine tests, one of which showed that the vaccine is 90% effective. Now doctors and scientists are trying to understand the effectiveness of the vaccine, and how it compares with rival vaccines.
Moderna and Pfizer have reported that their vaccines have an efficacy of around 95% in preventing COVID-19, although each test measures the figure differently.
The Oxford-AstraZeneca vaccine candidate is given to people in two doses, at least one month apart. Trial data, coming from late-stage studies in the UK, Brazil and South Africa, suggest that the vaccine is 62% effective if people receive two full doses, but 90% effective when they receive a half-power version of the first dose.
The information was provided through a press release and has not been published in a peer-reviewed journal. AstraZeneca and Oxford said they are submitting the results for review and publication.
The Oxford University team does not know the exact reason for the different efficacy figures, but plans to investigate it further, has assured Sarah Gilbert, a professor of vaccinology who heads the Oxford team.
"We will be digging into the details of why exactly we get better efficacy with half dose and then full dose," he explained.
Gilbert has ventured that perhaps the half-dose regimen "best mimics what happens in a real infection."
"It could be that by giving a small amount of the vaccine to start with and going on with a large amount, it's a better way to kick-start the immune system and give us the strongest immune response, and the most effective immune response," he said.
Around 2,741 participants in the trial received the medium-potency version of the vaccine first, and all were in the UK, AstraZeneca has explained.
Dr Andrew Pollard, director of the Oxford Vaccine Group, says Oxford scientists originally thought two high doses would cause the best response, so Pollard notes the results are " intriguing."
Katie Ewer, associate professor and senior immunologist at the Edward Jenner Institute for Vaccine Research is a key member of the Oxford Vaccine team.
She has assured Business Insider that it is too late to use these results to make changes to the UK essay. But researchers could try to test the strength of the lower dose in the large late-stage study it is currently recruiting in the United States, he noted.
"They may decide to use low dose and standard dose, or they may decide to analyze low dose and low dose," he explained.
Pollard has pointed out that it is too early to say for sure whether there are real differences in the effectiveness of the Oxford-AstraZeneca vaccine and rival vaccines. He stressed that each trial makes different decisions, for example, on how to measure effectiveness, making it difficult to compare the figures for different trials.
Still, Dr. Anthony Fauci, director of the National Institute of Allergy and Infectious Diseases in the United States and a visible face in the country of the fight against the pandemic, has told STAT News that he is concerned who will receive each vaccine, if the Oxford-AstraZeneca vaccine turns out to be less effective.
"If it's 70%, then we have a dilemma," Fauci acknowledged. "Because, what are you going to do with 70% when you have two [vaccines] that are 95%? Who are you going to give a vaccine like that to?"
Different vaccines have unique characteristics and will likely be used in different locations and populations. For example, preliminary results suggest that the Oxford-AstraZeneca candidate works best in older adults. It also doesn't need very cold temperatures, so it might be the best choice for middle and low income countries that can't afford cold storage, and it's less expensive.
In addition, there are likely to be many more doses available of the Oxford-AstraZeneca vaccine than that of Moderna or Pfizer. AstraZeneca has said it plans to be able to make up to 3,000 million doses next year.
For now, there will be a demand that exceeds any of the vaccines, AstraZeneca CEO Pascal Soriot said on Monday.
"If you add the capacity that Pfizer has announced, plus the capacity announced by modern, plus our capacity, which is much larger, the 3 we do not even have enough vaccine production for the world," he warned.